摘要 : Chitosan microspheres with lappaconitine hydrobromide were obtained by ionotropic gelation with sodium tripolyphosphate as a crosslinking agent. The efficiency of microencapsulation, i.e., the proportion of substance encapsulated ... 展开 Chitosan microspheres with lappaconitine hydrobromide were obtained by ionotropic gelation with sodium tripolyphosphate as a crosslinking agent. The efficiency of microencapsulation, i.e., the proportion of substance encapsulated inside the capsules of the initial amount was determined by a direct method. The release of the antiarrhythmic drug from the microspheres under conditions simulating the gastrointestinal tract was studied. Lappaconitine hydrobromide was microencapsulated by biopolymers from solutions during the study. The prepared microspheres were found to be free flowing and have a high capture rate and high percentage yield. It has been proven that polyelectrolyte microencapsulation makes it possible to obtain new sustained-release dosage forms of the antiarrhythmic drug lappaconitine hydrobromide for oral administration. The developed microsphere form of the antiarrhythmic drug can maintain a therapeutic concentration in the body for a longer time, which allows the frequency of drug administration and its toxic action to be reduced. 收起